From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade namesNulojix
AHFS/Drugs.comConsumer Drug Information
License data
  • US: C (Risk not ruled out)
Routes of
ATC code
Legal status
Legal status
  • none
 ☒N☑Y (what is this?)  (verify)

Belatacept (trade name Nulojix) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[1] which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant[2] survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only 2 amino acids.

Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration on June 15, 2011.[3]


  1. ^ " CTLA-4 Strategies". Archived from the original on 5 December 2008. Retrieved 2008-10-24.
  2. ^ Vincenti, Flavio; Rostaing, Lionel; Grinyo, Joseph; Rice, Kim; Steinberg, Steven; Gaite, Luis; Moal, Marie-Christine; Mondragon-Ramirez, Guillermo A.; Kothari, Jatin; Polinsky, Martin S.; Meier-Kriesche, Herwig-Ulf; Munier, Stephane; Larsen, Christian P. (2016). "Belatacept and Long-Term Outcomes in Kidney Transplantation | NEJM". New England Journal of Medicine. 374 (4): 333–343. doi:10.1056/NEJMoa1506027. PMID 26816011.
  3. ^ "FDA approves Nulojix for kidney transplant patients" (Press release). U.S. Food and Drug Administration. 2011-06-15. Archived from the original on 19 June 2011. Retrieved 2011-06-16.